



maintrac

maintrac – the blood test
for monitoring your
breast cancer therapy



simfo

Is your therapy effective?

Is there a risk of developing recurrence?

These are the most important questions from you.

With maintrac, our mission is to help you answer these questions.

All that is required from you is a 15 ml sample of EDTA blood.

maintrac offers you the following advantages:

- *early detection of renewed tumour activity*
- *monitoring of therapy*
- *adjustment of therapy*
- *long-term follow-up even after the completion of therapy*




Image above:

Vital tumour cells are stained fluorescent green in the blood test.

Dying tumour cells are also stained fluorescent red.

maintrac



maintrac – the blood test for monitoring breast cancer maintenance therapy.

Every cancer is different and the efficacy of the medications used varies with each treatment. Therefore, it is important to monitor the success of the therapy used in the long term.

Cancer releases tumour cells, circulating tumour cells, into the blood. Tumour cells may still be present in blood years after surgery or therapy.

maintrac is a highly sensitive diagnostic method based on circulating tumour cells. It facilitates the monitoring of tumour activity.

maintrac provides information on the efficacy of the endocrine therapy used.

maintrac helps you to make a decision about whether long-term therapy is sensible.

Further information on maintrac can be found on www.maintrac.com


maintrac monitors the success of your endocrine therapy.

With a blood test, maintrac can detect increasing tumour activity earlier than other methods by identifying an increase in the number of cells.

With maintrac, the treating physician has an additional tool for the regular monitoring of tumour activity (every 3- 6 months).

In the case of an increase in the number of cells, endocrine therapy can be modified (tamoxifen vs. aromatase inhibitor).

Behaviour of circulating tumor cells



During the course of the disease the cell number can be tested repeatedly.

Increasing cell numbers = further diagnostics / optimisation of the therapy

Constant cell numbers = positive course of disease


Decreasing cell numbers = good prognosis / efficient therapy

Full details and further actions should be discussed with your treating physician.

Is an extension of endocrine therapy useful?


It does not always make sense to use long-term therapy e.g. with tamoxifen for more than 5 years. Re extent to which a patient can benefit from further treatment can be assessed using maintrac.

Breast cancer long-term monitoring with maintrac: example 1



A subsequent increase in tumour cells after the end of therapy was succeeded by disease recurrence.

Breast cancer patient under long-term monitoring with maintrac: example 2



Minor changes are currently seen as being positive.

After completion of therapy, an increase in the number of circulating tumour cells may indicate that it may be useful to consider resumption of therapy.

Your competent partner
in Oncology and Hemostaseology.



simfo

*Specialised Immunology
Research and Development GmbH*

*In association with
Transfusion Medicine Center
Bayreuth (TZB)*

*Kurpromenade 2
95448 Bayreuth, Germany
Phone: +49 (0) 921 730052-10
mail@simfo.com
www.simfo.com*

*Specialised Medical Laboratory
Dr. Pachmann*

*Kurpromenade 2
95448 Bayreuth, Germany
Phone: +49 (0) 921 850200*

*Est. 2005, maintrac is performed by the DIN
EN ISO 15189 accredited specialized medical
laboratory Dr. Pachmann.*